Ads
related to: difference between hypafix and fixomull drug information
Search results
Results From The WOW.Com Content Network
For prescription medications, the insert is technical, providing information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user —the person who will take the ...
The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BLA) was a 2005 landmark trial that compared the effects of the established therapy of the combination of atenolol and bendroflumethiazide to the new drug combination of amlodipine and perindopril (trade names Viacoram, AceryCal etc.). [12]
Tamsulosin – ARISTO Pharma – 0.4 mg prolonged-release tablets – Urologikum. Tamsulosin, sold under the brand names including Flomax and Contiflo, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones.
Last but not least, the expert advised seeking information from a trusted healthcare provider, who will be well-equipped to answer any questions and fact-check information sources. “[I]f you ...
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
Some drugs are absorbed better in certain parts of the digestive system. If this part is the stomach, a coating is selected that dissolves quickly and easily in acid. If the rate of absorption is best in the large intestine or colon, a coating is used that is acid resistant and dissolves slowly to ensure that the tablet reaches that point ...
Even after the drug is released, it will still be monitored for performance and safety risks. The manufacture process must satisfy the FDA's "Good Manufacturing Practices", which are typically manufactured in a cleanroom environment with strict limits on the amount of airborne particles and other microbial contaminants that may alter the ...
Even slight differences in manufacturing might result in therapeutic or safety differences not to be attributed to a known or defined component. The existing and defined biosimilar pathway , taking into consideration the complexity of biologics and its follow-on products, is neither applicable for NBCDs and its similars.